The recipient of the 2025 Donald Metcalf Award is Dr. Constanze 'Conny' Bonifer, for her outstanding work in the fields of epigenetic and gene regulatory processes regulating blood cell development and differentiation, and how these processes go astray in the development of blood cancer. Dr. Bonifer has been a pioneer and world leader in these areas and a source of inspiration and guidance for many scientists working in experimental hematology.
Dr. Bonifer started her scientific career in Germany where she completed her BSc in Cologne and her PhD in Heidelberg. After a postdoctoral fellowship at the Karolinska Institute, Stockholm, Sweden and the National Institute of Medical Research, London, UK, Dr. Bonifer returned to Germany as an Assistant Professor at the University of Freiburg. She next relocated her group to the University of Leeds, UK, where she became the Head of Section of Experimental Haematology, and subsequently took up the Chair of Experimental Haematology at the Institute of Cancer and Genomic Sciences at the University of Birmingham, UK. Dr. Bonifer is currently Emeritus Professor of Experimental Haematology at the University of Birmingham and Principal Research Fellow at Murdoch Children's Research Institute (MCRI). In addition to her academic roles, she has given her time generously to the success of ISEH, serving on several committees, including the Board of Directors, and in encouraging and supporting ISEH junior investigators at our annual meetings.
Dr. Bonifer has made many seminal contributions to our understanding of how epigenetic processes and transcription factors regulate blood cell development. Her early work on identifying individual gene contributions provided important insights into the molecular principles of enhancers in developmentally controlled gene regulation. She has been a pioneer in using molecular biology and genome wide 'omics' techniques combined with systems biology and mathematical modelling, to identify gene regulatory networks that establish and maintain blood cell fates. This work ultimately uncovered the mechanisms by which key transcription factors, like Runx1, play in these processes. In parallel, Dr. Bonifer applied her sophisticated insights and knowledge to make new inroads into our understanding of how deregulation of blood cell development contributes to leukemogenesis. Her early beliefs that transcriptional malfunction was at the heart of tumorigenesis, strongly shaped the cancer epigenetics field. Finally, her studies of the transcriptional regulation of blood cell development in mouse embryonic stem cells, provides essential clues about blood cell differentiation derived from human ES/iPSC cells. Dr. Bonifer has been an inspiring pioneer and innovator who has driven the field forward with her many seminal contributions, and continues to be a role model for the next generations of experimental hematologists.